

Online Supplementary Material

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease.
JHEOR. 2024;11(1):23-31. [doi:10.36469/jheor.2024.92028](https://doi.org/10.36469/jheor.2024.92028)

Appendix: Treatment Survey to Determine Standard of Care

Figure S1: Markov Trace of the Extracorporeal Photopheresis Arm

Figure S2: Markov Trace of the Standard of Care Arm

This supplementary material has been provided by the authors to give readers additional information about their work.



Background information

1. Please complete the following details

- Name

- Hospital/Organisation

- State

- Post Code

- Qualification

- Years of experience treating cGVHD patients:

- 1-5
- 5-10
- 10-20
- 20-30
- 30+

- Number of cGVHD patients treated per year

- Number of newly diagnosed cGVHD patients treated each year

- Email address

Treatment pathways

PLEASE ASSUME ECP IS NOT AVAILABLE FOR USE WHEN ANSWERING THE FOLLOWING QUESTIONS:

2. For adult patients diagnosed with steroid-refractory or steroid-intolerant cGVHD what are the estimated proportions (in percent) of therapies listed below used in the **second-line** (after treatment with systemic steroids) setting?

- Mycophenolate mofetil: %
- Tacrolimus: %
- Sirolimus: %
- Ciclosporin: %
- Methotrexate: %
- Rituximab: %
- Ibrutinib: %
- Ruxolitinib: %
- Imatinib: %
- Interferon: %
- Other, please specify:

Drug name:

Proportion: %

3. For adult patients diagnosed with steroid-refractory or steroid-intolerant cGVHD what are the estimated proportions (in percent) of therapies listed below used in the **third-line** setting?

- Mycophenolate mofetil: %
- Tacrolimus: %
- Sirolimus: %
- Ciclosporin: %
- Methotrexate: %
- Rituximab: %
- Ibrutinib: %
- Ruxolitinib: %
- Imatinib: %
- Interferon: %

- Pulsed corticosteroids: %

- Other, please specify:

Drug name:

Proportion: %

4. Do you agree that ECP will be placed as a second-line therapy (i.e. used amongst other treatments listed in question 2)?

Yes

No

If no, please provide rationale:

5. Do you agree that ECP will be used concomitantly with other second-line therapies?

Yes

No

If no, please provide rationale:

Thank you for completing the survey.

Figure S1. Markov Trace of the Extracorporeal Photopheresis Arm




Figure S2. Markov Trace of the Standard of Care Arm

